MWVC
Morgens Waterfall Vintiadis & Co Portfolio holdings
AUM
$136M
This Quarter Return
+24.69%
1 Year Return
+103.3%
3 Year Return
+567.71%
5 Year Return
+1,003.82%
10 Year Return
+9,424.15%
AUM
$142M
AUM Growth
+$142M
(+9%)
Cap. Flow
-$10.4M
Cap. Flow
% of AUM
-7.31%
Top 10 Holdings %
Top 10 Hldgs %
41.98%
Holding
56
New
5
Increased
9
Reduced
8
Closed
8
Top Buys
| 1 |
Caesars Entertainment
CZR
|
$4.77M |
| 2 |
PARA
Paramount Global Class B
PARA
|
$3.69M |
| 3 |
Adobe
ADBE
|
$3.63M |
| 4 |
Meta Platforms (Facebook)
META
|
$3.08M |
| 5 |
Okta
OKTA
|
$1.6M |
Top Sells
| 1 |
McDonald's
MCD
|
$5M |
| 2 |
CZR
Caesars Entertainment Corporation
CZR
|
$4.43M |
| 3 |
Synopsys
SNPS
|
$4.12M |
| 4 |
Twilio
TWLO
|
$4M |
| 5 |
American Tower
AMT
|
$3.1M |
Sector Composition
| 1 | Technology | 36.3% |
| 2 | Consumer Discretionary | 20.6% |
| 3 | Healthcare | 16.7% |
| 4 | Communication Services | 15.92% |
| 5 | Financials | 5.9% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
ADMA Biologics
ADMA
$4.12B
| $2.4M | 1.63% |
600,000
+50,000
| +9% | +$200K |
|
27
UnitedHealth
UNH
$281B
| $2.03M | 1.38% |
6,900
+1,500
| +28% | +$441K |
|
28
Mastercard
MA
$538B
| $1.94M | 1.32% |
6,500
| – | – |
|
29
Medtronic
MDT
$119B
| $1.7M | 1.16% |
15,000
| – | – |
|
30
Illumina
ILMN
$15.8B
| $1.66M | 1.13% |
5,000
| – | – |
|
31
Thermo Fisher Scientific
TMO
$186B
| $1.62M | 1.1% |
5,000
| – | – |
|
32
Esperion Therapeutics
ESPR
$448M
| $1.19M | 0.81% |
+20,000
| New | +$1.19M |
|
33
Heron Therapeutics
HRTX
$207M
| $1.18M | 0.8% |
50,000
+11,000
| +28% | +$259K |
|
34
Agios Pharmaceuticals
AGIO
$2.19B
| $1M | 0.68% |
+21,000
| New | +$1M |
|
35
Neurocrine Biosciences
NBIX
$13.8B
| $967K | 0.66% |
+9,000
| New | +$967K |
|
36
Labcorp
LH
$23.1B
| $947K | 0.64% |
5,600
| – | – |
|
37
AstraZeneca
AZN
$248B
| $643K | 0.44% |
12,900
| – | – |
|
38
JPMorgan Chase
JPM
$829B
| $638K | 0.43% |
4,575
| – | – |
|
39
CRISPR Therapeutics
CRSP
$4.71B
| $609K | 0.41% |
10,000
| – | – |
|
40
TherapeuticsMD
TXMD
$12.8M
| $605K | 0.41% |
250,000
+138,000
| +123% | +$334K |
|
41
Merck
MRK
$210B
| $568K | 0.39% |
6,240
| – | – |
|
|
MGP
42
DELISTED
MGM Growth Properties LLC Class A common shares representing limited liability company interests
MGP
| $534K | 0.36% |
17,250
-15,000
| -47% | -$464K |
|
43
Boeing
BA
$177B
| $489K | 0.33% |
1,500
| – | – |
|
44
BP
BP
$90.8B
| $473K | 0.32% |
12,532
| – | – |
|
|
RDS.B
45
DELISTED
Royal Dutch Shell PLC ADS Class B
RDS.B
| $467K | 0.32% |
7,792
| – | – |
|
46
Editas Medicine
EDIT
$231M
| $444K | 0.3% |
15,000
| – | – |
|
47
VICI Properties
VICI
$36B
| $440K | 0.3% |
17,230
-32,000
| -65% | -$817K |
|
|
CLLS
48
Cellectis
CLLS
$258M
| $291K | 0.2% |
17,000
| – | – |
|
|
49
American Tower
AMT
$95.5B
| – | – |
-14,000
| Closed | -$3.1M |
|
50
Home Depot
HD
$405B
| – | – |
-13,000
| Closed | -$3.02M |
|